Drug search by name

Docefrez and Myelosuppression

Result of checking the interaction of drug Docefrez and disease Myelosuppression for safety when used together.

Check result:

Docefrez <> Myelosuppression

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of docetaxel is contraindicated in patients with a neutrophil count < 1500/mm3. Docetaxel induces dose-related myelosuppression resulting in neutropenia, thrombocytopenia, and anemia. Neutropenia occurs in all patients administered 60-100 mg/m2 of docetaxel. Grade 4 neutropenia (< 500/mm3) occurs in nearly all patients administered 100 mg/m2 of docetaxel. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, or local infection. Therapy should be administered cautiously to patients with compromised bone marrow reserve and should be withheld until neutrophil levels is > 1500/mm3 and/or platelet counts is > 100,000/mm3. A 25% reduction in dosage is recommended during subsequent cycles following severe neutropenia (< 500/mm3). It is recommended to performed frequent blood cell counts on all patients receiving docetaxel.

References:

Bissett D, Kaye SB "Taxol and taxotere--current status and future prospects." Eur J Cancer 29a (1993): 1228-31
"Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
Ravdin PM, Valero V "Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer." Semin Oncol 22 (2 suppl) (1995): 17-21

Docefrez

Generic Name: docetaxel

Brand Name: Docefrez, Taxotere

Synonyms: n.a.

What is Docefrez?